These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30588904)

  • 41. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Norton JC; Chi-Burris K; Demos G
    CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis.
    Srisurapanont M; Suradom C; Suttajit S; Kongsaengdao S; Maneeton B
    Gen Hosp Psychiatry; 2024; 87():124-133. PubMed ID: 38412585
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study.
    Layton JB; Forns J; McQuay LJ; Danysh HE; Dempsey C; Anthony MS; Turner ME
    Drug Saf; 2023 Feb; 46(2):195-208. PubMed ID: 36517664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice.
    Dashtipour K; Gupta F; Hauser RA; Karunapuzha CA; Morgan JC
    Parkinsons Dis; 2021; 2021():2603641. PubMed ID: 33489083
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parkinson's disease psychosis: presentation, diagnosis and management.
    Schneider RB; Iourinets J; Richard IH
    Neurodegener Dis Manag; 2017 Dec; 7(6):365-376. PubMed ID: 29160144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study.
    Alva G; Cubała WJ; Berrio A; Coate B; Abler V; Pathak S
    J Alzheimers Dis; 2024; 98(1):265-274. PubMed ID: 38427485
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review.
    Kyle K; Bronstein JM
    Parkinsonism Relat Disord; 2020 Jun; 75():55-62. PubMed ID: 32480308
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trial of Pimavanserin in Dementia-Related Psychosis.
    Tariot PN; Cummings JL; Soto-Martin ME; Ballard C; Erten-Lyons D; Sultzer DL; Devanand DP; Weintraub D; McEvoy B; Youakim JM; Stankovic S; Foff EP
    N Engl J Med; 2021 Jul; 385(4):309-319. PubMed ID: 34289275
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments.
    Rojas M; Chávez-Castillo M; Duran P; Ortega Á; Bautista-Sandoval MJ; Salazar J; Riaño-Garzón M; Chacín M; Medina-Ortiz O; Palmar J; Cudris-Torres L; Bermúdez V
    Curr Pharm Des; 2022; 28(33):2725-2741. PubMed ID: 36321314
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial.
    Weintraub D; Espay AJ; Sharma VD; Tariot PN; Abler V; Pathak S; Stankovic S
    Parkinsonism Relat Disord; 2024 Feb; 119():105951. PubMed ID: 38113700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Parkinson's disease psychosis management: an evidence based, experience informed, pragmatic approach.
    Friedman JH
    Expert Opin Pharmacother; 2024 Feb; 25(2):149-156. PubMed ID: 38344806
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pimavanserin use in a movement disorders clinic: a single-center experience.
    Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N
    Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.
    Samudra N; Patel N; Womack KB; Khemani P; Chitnis S
    Drugs Aging; 2016 Dec; 33(12):855-863. PubMed ID: 27830568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pimavanserin: First Global Approval.
    Markham A
    Drugs; 2016 Jul; 76(10):1053-7. PubMed ID: 27262680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of Parkinson's Disease Psychosis.
    Elsibai H; Kualleny M; Fandy TE
    Sr Care Pharm; 2022 Aug; 37(8):339-344. PubMed ID: 35879841
    [No Abstract]   [Full Text] [Related]  

  • 57. Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis.
    Isaacson SH; Pahwa R; Pagan F; Abler V; Truong D
    Clin Park Relat Disord; 2024; 10():100256. PubMed ID: 38770047
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.
    Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S
    Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication.
    Davis J; Zamora D; Horowitz M; Leucht S
    Expert Opin Pharmacother; 2021 Sep; 22(13):1651-1660. PubMed ID: 34404290
    [No Abstract]   [Full Text] [Related]  

  • 60. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
    McFarland K; Price DL; Bonhaus DW
    Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.